ProGrow Pharma (PGP) Partners is a professional team of all kinds of specialists that offers exclusive advisory services to healthcare business. Over a decade it has been researching healthcare and biotechnological sectors at the global market to provide key players with in-depth data and feasible solutions. In addition, ProGrow Pharma studies the investment environment within the sector to ensure effective cooperation between the investors and firms that solicit for financing support. PGP has years-long partnership relations with firms engaged in the pharma industry:
- Market leaders
- CROs
- Innovators
- Venture Capitalists
- Private Equity investors
The company employs viable estimating methods and other effective methodology to assist clients in maximizing their business potential. PGP experts have in-depth knowledge of the scientific innovations, the production of drugs, medical trials, and the status of therapeutical, molecular and other specific medical development.
Apart from research and development in the healthcare sector PGP monitors its competitive landscape, supply, and demand, product launch and other technical and financial activities of the key participants.
The research we provide covers all geographies and focuses on such knowledge as:
- Mergers and Acquisitions
- Due Diligence
- Financial Risks and Opportunities
- Growth Drivers
- Start-ups Evaluation
- Brad Development
- Strategic Partnership
- Regulatory Policies in the sector
- Product Launch
- Operational Potential
- Fund Raising Options
The reports you can order form us will contain the information which is feature-oriented for your company. Our offerings are reasonably priced and delivered on time helping you to identify challenges and evaluate opportunities on the market.
Publications found:
7
Sort by:
Parkinson's Disease: Molecular Landscape & Future Disease Modifying Targeted Therapies
US$ 3,200.00
... making we are publishing our latest in the series“ Parkinson's Disease -Molecular Landscape & Future Disease Modifying Targeted Therapies” The success of targeted therapies in ... PD but few which are comprehensive both in defining the molecular landscape in PD, unmet need, promising drugs in the pipeline their ...
September 2018
34 pages
Innovation in India Series: An Analysis of Select Pharma Biotech Start-ups
US$ 2,500.00
... west IPO is not the popular route of raising capital in India for innovator companies as the public perception, appreciation and understanding of the ... worldwide. We elaborate on this urgent need and the potential of an innovative antibiotic for serious infections. ii) Vitas Pharma also focuses on developing ...
February 2018
40 pages
Therapeutic Class Report: Oral Mucositis
US$ 3,000.00
... , there are very few targeted drugs or therapeutic options available to the patient. Untreated it can ... a grave need for systematic management of oral mucositis triggered by anti-neoplastic protocols. Several products ... literature, industry publications, company reports and published information, and statistical ...
September 2017
41 pages
